Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry

Autor: Toru Kida, Hitomi Kaneko, Toshimitsu Matsui, Miki Kiyota, Shin-ichi Fuchida, Shosaku Nomura, Takae Kohara, Kansai Myeloma Forum Investigators, Nobuhiko Uoshima, Ryoichi Takahashi, Yoko Adachi, Kazunori Imada, Kensuke Ohta, Satoru Kosugi, Hirokazu Tanaka, Mitsuhiro Matsuda, Masato Iida, Akifumi Takaori-Kondo, Junya Kanda, Hideo Yagi, Hitoji Uchiyama, Masayuki Hino, Hirohiko Shibayama, Yuji Shimura, Yuzuru Kanakura, Katsuya Wada, Junya Kuroda, Takahiro Karasuno, Aya Nakaya, Itaru Matsumura, Maki Shindo, Chihiro Shimazaki
Rok vydání: 2020
Předmět:
Zdroj: International Journal of Hematology. 112:666-673
ISSN: 1865-3774
0925-5710
Popis: We retrospectively analyzed 51 patients with solitary plasmacytoma diagnosed from October 2002 to September 2018 from a cohort of 3575 patients with plasma cell dyscrasias registered in the Kansai Myeloma Forum. Twenty-seven patients had solitary bone plasmacytoma (SBP) and 24 had extramedullary plasmacytoma (EMP), with prevalence of 0.8% and 0.7%, respectively. The most frequent M protein was IgG (40%) in SBP, whereas non-secretory proteins were most frequent (50%) in EMP. Five-year overall survival was 78.2% in SBP and 80.8% in EMP (P = 0.894). Among patients with SBP, 44% progressed to MM with a median time of 10.5 months (2.4–93.3 months), whereas 8% of EMP patients progressed to MM with a median time of 18.6 months (13.0–24.2 months). The most frequent treatment was radiotherapy (41%) or observation (41%) in SBP, and chemotherapy (54%) in EMP. No statistically significant difference was observed upon univariate analysis of prognostic factors including age, sex, performance status, and IgG M protein. Our results suggest that there are biological differences between SBP and EMP in real-world settings.
Databáze: OpenAIRE
Externí odkaz: